Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Ac225-DOTA-M5A
/
City of Hope, National Cancer Institute - Bethesda
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
Ac225-DOTA-M5A - City of Hope, National Cancer Institute
/
Bethesda
Trial completion date, Trial primary completion date, Metastases:
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov) - Mar 5, 2024
P1
, N=20, Recruiting,
Sponsor: City of Hope Medical Center
Trial completion date: Mar 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Aug 2025
|
|||||||||
Ac225-DOTA-M5A - City of Hope, National Cancer Institute
/
Bethesda
Enrollment open, Metastases:
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov) - Jun 8, 2022
P1
, N=20, Recruiting,
Sponsor: City of Hope Medical Center
Trial completion date: Mar 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Aug 2025 Not yet recruiting --> Recruiting
|
|||||||||
Ac225-DOTA-M5A - City of Hope, National Cancer Institute
/
Bethesda
Trial initiation date, Metastases:
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov) - Apr 12, 2022
P1
, N=20, Not yet recruiting,
Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Initiation date: Mar 2022 --> Jul 2022
|
|||||||||
Ac225-DOTA-M5A - City of Hope, National Cancer Institute
/
Bethesda
New P1 trial, Metastases:
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
(clinicaltrials.gov) - Jan 24, 2022
P1
, N=20, Not yet recruiting,
Sponsor: City of Hope Medical Center